var data={"title":"Regadenoson: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Regadenoson: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/352050?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=regadenoson-patient-drug-information\" class=\"drug drug_patient\">see &quot;Regadenoson: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139005\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Lexiscan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6156884\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Diagnostic Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139064\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Myocardial perfusion imaging:</b> IV: 0.4 mg as a single dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139065\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14210990\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to severe impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dialysis: Dialyzable; no dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14210991\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139070\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lexiscan: 0.4 mg/5 mL (5 mL) [contains edetate disodium dihydrate, propylene glycol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139007\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139067\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Administer over ~10 seconds into a peripheral vein using a &ge;22-gauge catheter or needle, followed immediately by a 5 mL saline flush. Wait 10 to 20 seconds, then administer the radionuclide myocardial perfusion imaging agent. The radionuclide may be injected directly into the same catheter as regadenoson.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139008\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Radionuclide myocardial perfusion imaging:</b> A pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139017\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac conduction disturbance (20% to 26%), tachycardia (22%), flushing (16%), ventricular premature contractions (14%), chest discomfort (13%), angina (&le;12%), depression of ST segment on ECG (&le;12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (28%; COPD patients 18%; asthma patients 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrial premature contractions (7%), chest pain (7%), systolic hypotension (7%; &gt;35 mm Hg), ventricular conduction abnormalities (6%), systolic hypertension (5%; &ge;180 mm Hg and &ge;20 mm Hg from baseline), decreased diastolic blood pressure (4%; &gt;25 mm Hg), first degree atrioventricular block (PR prolongation &gt;220 msec; 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness (8%), feeling hot (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (6%), abdominal distress (5%), dysgeusia (5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Respiratory distress (13% to 19%; in patients with asthma or COPD), wheezing (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, anaphylaxis, acute coronary syndrome, angioedema, asystole, atrioventricular conduction disturbance (other than AV blocks), bronchoconstriction, cardiac arrest, cerebrovascular accident (hemorrhagic and ischemic), diarrhea, fecal incontinence, heart block (including third-degree AV block), hypersensitivity reaction, hypertension, increased diastolic blood pressure (&ge;30 mm Hg), musculoskeletal pain, myalgia, myocardial infarction, oxygen desaturation, pharyngeal edema, prolonged Q-T interval on ECG (transient), respiratory arrest, second degree atrioventricular block, seizure, skin rash, supraventricular tachyrhythmia (includes atrial fibrillation or flutter), symptomatic hypotension, syncope, transient ischemic attacks, tremor, urticaria, ventricular arrhythmia, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9848303\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Second- or third-degree atrioventricular (AV) block or sinus node dysfunction in patients without a functioning artificial pacemaker</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139014\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse events:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Atrial fibrillation/flutter: New-onset or recurrent atrial fibrillation with rapid ventricular response and atrial flutter has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular effects: Hemorrhagic and ischemic cerebrovascular accidents have occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Conduction disturbances: May depress SA and AV node conduction and may produce first-, second-, or third-degree heart block, or sinus bradycardia. Third-degree heart block and asystole within minutes of administration have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Anaphylaxis, angioedema, cardiac  or respiratory arrest, respiratory distress, and other hypersensitivity reactions (eg, decreased oxygen saturation, hypotension, throat tightness, urticaria, rash) have occurred. Equipment for resuscitation and trained personnel experienced in handling serious hypersensitivity reactions should always be immediately available prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: May produce clinically significant hypertension; typically within minutes of administration and usually resolves within 10 to 15 minutes. Effects may persist; in some patients, hypertension continued for 45 minutes after administration. Use with caution in patients with underlying hypertension, especially when low-level exercise is used during MPI.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: May induce arterial vasodilation and hypotension. Use with caution in patients with autonomic dysfunction, hypovolemia, left main coronary artery stenosis, pericarditis, pericardial effusion,  stenotic valvular heart disease, or stenotic carotid artery disease with cerebrovascular insufficiency. Syncope and transient ischemic attacks have also been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial ischemia: Fatal and nonfatal myocardial infarction, ventricular arrhythmias, and cardiac arrest have occurred. Avoid use in patients with symptoms or signs of acute myocardial ischemia, unstable angina or cardiovascular instability; these patients may be at increased risk of serious cardiovascular reactions. Equipment for resuscitation and trained personnel experienced in handling cardiac emergencies should always be immediately available prior to administration. If serious reactions occur, consider the use of aminophylline, an adenosine antagonist.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory effects: May cause dyspnea, bronchoconstriction, and respiratory compromise. Equipment for resuscitation and appropriate bronchodilator (eg, albuterol) therapy should always be immediately available prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure: May lower the seizure threshold; new-onset or recurrence of seizures, some prolonged, has occurred.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; may have a higher incidence of regadenoson-induced hypotension.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299988\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139024\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9462&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminophylline: May diminish the vasodilatory effect of Regadenoson.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caffeine and Caffeine Containing Products: May diminish the vasodilatory effect of Regadenoson. Management: Avoiding using caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior to the administration of regadenoson.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May enhance the adverse/toxic effect of Regadenoson. Specifically, adenosine mediated effects may be enhanced.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline: May diminish the vasodilatory effect of Regadenoson.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139010\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139013\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if regadenoson is excreted in breast milk. Due to the potential for serious adverse effects in the nursing infant, the manufacturer recommends interrupting nursing for 10 hours after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139066\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid dietary caffeine for at least 12 hours prior to pharmacologic stress testing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139069\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, blood pressure, continuous cardiac monitoring, oxygen saturation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139030\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Regadenoson, a low affinity agonist of the A<sub>2A</sub> adenosine receptor, increases coronary blood flow (CBF) and mimics the increase in CBF caused by exercise. Myocardial uptake of the radiopharmaceutical is proportional to CBF creating the contrast required to identify stenotic coronary arteries.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6139033\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: 11.5 L (Gordi, 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Unknown</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Initial phase: 2 to 4 minutes; Intermediate phase: 30 minutes; Terminal phase: 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, plasma: 1 to 4 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (57% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16321820\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lexiscan Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/5 mL (5 mL): $284.44</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12992806\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Rapiscan (AT, CZ, DE, DK, EE, ES, FR, GB, HR, IE, LT, MT, NL, NO, PL, PT, SE, SI, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Society of Nuclear Cardiology, &ldquo;Imaging Guidelines for Nuclear Cardiology Procedures: A Report of The American Society of Nuclear Cardiology Quality Assurance Committee,&rdquo; <i>J  Nucl Cardiol</i>, 2006, 13(6):e21-171.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gordi T, Frohna P, Sun HL, et al. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. <i>Clin Pharmacokinet</i>. 2006;45(12):1201-1212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/regadenoson-drug-information/abstract-text/17112296/pubmed\" target=\"_blank\" id=\"17112296\">17112296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iskandrian AE, Bateman TM, Belardinelli L, et al, &ldquo;Adenosine Versus Regadenoson Comparative Evaluation in Myocardial Perfusion Imaging: Results of the ADVANCE Phase 3 Multicenter International Trial,&rdquo; <i>J Nucl Cardiol</i>, 2007, 14(5):645-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/regadenoson-drug-information/abstract-text/17826318/pubmed\" target=\"_blank\" id=\"17826318\">17826318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lexiscan (regadenoson) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; January 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9462 Version 86.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F6139005\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F6156884\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F6139064\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F6139065\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F14210990\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F14210991\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F6139070\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F6139007\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F6139067\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F6139008\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F6139017\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9848303\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F6139014\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299988\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6139024\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6139010\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F6139013\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F6139066\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F6139069\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F6139030\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F6139033\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16321820\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F12992806\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9462|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=regadenoson-patient-drug-information\" class=\"drug drug_patient\">Regadenoson: Patient drug information</a></li></ul></div></div>","javascript":null}